Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
HIV Infections | 75 | 2024 | 17531 | 1.570 |
Why?
|
Antiretroviral Therapy, Highly Active | 16 | 2020 | 1899 | 1.470 |
Why?
|
Anti-HIV Agents | 41 | 2020 | 4558 | 1.330 |
Why?
|
Acquired Immunodeficiency Syndrome | 17 | 2015 | 2204 | 1.060 |
Why?
|
HIV-1 | 31 | 2021 | 6945 | 1.010 |
Why?
|
Anti-Retroviral Agents | 12 | 2020 | 1786 | 0.930 |
Why?
|
Paraparesis, Tropical Spastic | 1 | 2023 | 32 | 0.880 |
Why?
|
Human T-lymphotropic virus 1 | 1 | 2023 | 143 | 0.830 |
Why?
|
Viral Load | 23 | 2023 | 3385 | 0.760 |
Why?
|
Peripheral Nervous System Diseases | 6 | 2020 | 710 | 0.730 |
Why?
|
Hepatitis C, Chronic | 6 | 2023 | 1032 | 0.690 |
Why?
|
CD4 Lymphocyte Count | 20 | 2021 | 2586 | 0.630 |
Why?
|
Exanthema | 1 | 2023 | 503 | 0.620 |
Why?
|
Hepatitis C | 9 | 2023 | 1596 | 0.600 |
Why?
|
Benzoxazines | 12 | 2015 | 320 | 0.550 |
Why?
|
Reverse Transcriptase Inhibitors | 9 | 2013 | 618 | 0.540 |
Why?
|
Telephone | 3 | 2013 | 627 | 0.410 |
Why?
|
Hepacivirus | 10 | 2023 | 1343 | 0.390 |
Why?
|
Iron | 1 | 2020 | 1811 | 0.390 |
Why?
|
Tenosynovitis | 1 | 2011 | 57 | 0.380 |
Why?
|
Nelfinavir | 8 | 2011 | 68 | 0.370 |
Why?
|
Syphilis | 2 | 2010 | 243 | 0.360 |
Why?
|
Herpes Zoster | 2 | 2014 | 252 | 0.340 |
Why?
|
Eye Infections | 1 | 2010 | 63 | 0.340 |
Why?
|
Medication Adherence | 8 | 2016 | 2190 | 0.330 |
Why?
|
Arteritis | 2 | 2024 | 160 | 0.310 |
Why?
|
Proguanil | 1 | 2007 | 11 | 0.300 |
Why?
|
Atovaquone | 1 | 2007 | 56 | 0.290 |
Why?
|
Babesia microti | 1 | 2007 | 31 | 0.290 |
Why?
|
Treatment Failure | 9 | 2016 | 2653 | 0.290 |
Why?
|
Fever | 4 | 2024 | 1607 | 0.290 |
Why?
|
Patient Compliance | 4 | 2013 | 2693 | 0.280 |
Why?
|
Genetic Variation | 3 | 2020 | 6612 | 0.280 |
Why?
|
Oxazines | 6 | 2006 | 358 | 0.280 |
Why?
|
Stavudine | 5 | 2014 | 85 | 0.270 |
Why?
|
Body Image | 3 | 2020 | 645 | 0.270 |
Why?
|
Babesiosis | 1 | 2007 | 92 | 0.270 |
Why?
|
HIV-Associated Lipodystrophy Syndrome | 4 | 2020 | 137 | 0.260 |
Why?
|
HIV | 6 | 2023 | 1587 | 0.260 |
Why?
|
Alkynes | 12 | 2015 | 326 | 0.260 |
Why?
|
Zidovudine | 6 | 2014 | 626 | 0.250 |
Why?
|
Interferon-alpha | 5 | 2013 | 909 | 0.250 |
Why?
|
Cyclopropanes | 12 | 2015 | 436 | 0.250 |
Why?
|
Antiviral Agents | 6 | 2023 | 3053 | 0.240 |
Why?
|
Lamivudine | 5 | 2014 | 368 | 0.240 |
Why?
|
Hemochromatosis | 3 | 2020 | 175 | 0.240 |
Why?
|
Immunocompromised Host | 2 | 2019 | 865 | 0.230 |
Why?
|
DNA, Mitochondrial | 4 | 2012 | 869 | 0.220 |
Why?
|
Adult | 66 | 2023 | 223088 | 0.220 |
Why?
|
CD4-Positive T-Lymphocytes | 10 | 2011 | 4405 | 0.220 |
Why?
|
Splenomegaly | 1 | 2024 | 191 | 0.220 |
Why?
|
Nurses | 1 | 2013 | 2504 | 0.220 |
Why?
|
T-Lymphocytes, Helper-Inducer | 5 | 2003 | 975 | 0.210 |
Why?
|
RNA, Viral | 14 | 2012 | 2866 | 0.210 |
Why?
|
Decision Support Systems, Clinical | 1 | 2012 | 1176 | 0.210 |
Why?
|
Common Variable Immunodeficiency | 1 | 2024 | 99 | 0.210 |
Why?
|
Drug Resistance, Viral | 5 | 2016 | 867 | 0.200 |
Why?
|
Abdominal Pain | 2 | 2019 | 1069 | 0.200 |
Why?
|
Humans | 114 | 2024 | 765926 | 0.190 |
Why?
|
Female | 70 | 2024 | 396141 | 0.190 |
Why?
|
Lymphoproliferative Disorders | 1 | 2005 | 526 | 0.190 |
Why?
|
Male | 71 | 2024 | 363815 | 0.190 |
Why?
|
Oxidoreductases, N-Demethylating | 2 | 2012 | 110 | 0.180 |
Why?
|
Genotype | 8 | 2023 | 13026 | 0.180 |
Why?
|
Diagnosis, Differential | 9 | 2024 | 12973 | 0.180 |
Why?
|
Middle Aged | 50 | 2024 | 223016 | 0.180 |
Why?
|
HIV-2 | 1 | 2021 | 156 | 0.180 |
Why?
|
AIDS-Related Opportunistic Infections | 3 | 2014 | 663 | 0.180 |
Why?
|
T-Lymphocyte Subsets | 1 | 2009 | 1812 | 0.180 |
Why?
|
Aryl Hydrocarbon Hydroxylases | 2 | 2012 | 246 | 0.170 |
Why?
|
AIDS Vaccines | 2 | 2004 | 898 | 0.170 |
Why?
|
Travel | 2 | 2017 | 806 | 0.170 |
Why?
|
Spironolactone | 1 | 2023 | 415 | 0.170 |
Why?
|
Pharyngitis | 1 | 2021 | 221 | 0.170 |
Why?
|
Tuberculosis, Gastrointestinal | 1 | 2019 | 20 | 0.160 |
Why?
|
Drug Therapy, Combination | 13 | 2015 | 6306 | 0.160 |
Why?
|
Liver Diseases | 2 | 2024 | 1304 | 0.160 |
Why?
|
CD8-Positive T-Lymphocytes | 11 | 2010 | 4641 | 0.160 |
Why?
|
Confusion | 1 | 2021 | 278 | 0.160 |
Why?
|
HLA-B Antigens | 2 | 2010 | 329 | 0.160 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2005 | 615 | 0.160 |
Why?
|
Lymphopenia | 1 | 2021 | 298 | 0.160 |
Why?
|
Receptors, Transferrin | 1 | 2020 | 300 | 0.160 |
Why?
|
Didanosine | 4 | 2007 | 151 | 0.160 |
Why?
|
Strongylida Infections | 1 | 2018 | 48 | 0.150 |
Why?
|
Elasticity Imaging Techniques | 1 | 2023 | 397 | 0.150 |
Why?
|
Ferritins | 1 | 2020 | 600 | 0.140 |
Why?
|
Liver | 3 | 2024 | 7559 | 0.140 |
Why?
|
Polyethylene Glycols | 3 | 2009 | 1189 | 0.140 |
Why?
|
Dideoxynucleosides | 2 | 2015 | 135 | 0.140 |
Why?
|
Treatment Outcome | 17 | 2024 | 65194 | 0.130 |
Why?
|
Radio Frequency Identification Device | 1 | 2015 | 24 | 0.130 |
Why?
|
T-Lymphocytes, Cytotoxic | 5 | 2003 | 1800 | 0.120 |
Why?
|
Heterozygote | 2 | 2020 | 2796 | 0.120 |
Why?
|
Standard of Care | 2 | 2016 | 568 | 0.120 |
Why?
|
Diabetes Mellitus | 2 | 2023 | 5889 | 0.110 |
Why?
|
HIV Antibodies | 1 | 2021 | 1337 | 0.110 |
Why?
|
Atherosclerosis | 2 | 2024 | 3419 | 0.110 |
Why?
|
Neuralgia | 1 | 2020 | 619 | 0.110 |
Why?
|
CD4-CD8 Ratio | 2 | 2012 | 114 | 0.110 |
Why?
|
RNA-Directed DNA Polymerase | 1 | 2013 | 222 | 0.100 |
Why?
|
Pneumonia, Pneumocystis | 1 | 2014 | 241 | 0.100 |
Why?
|
Encephalitis, Viral | 1 | 2013 | 59 | 0.100 |
Why?
|
Rabies | 1 | 2013 | 56 | 0.100 |
Why?
|
Reminder Systems | 2 | 2012 | 388 | 0.100 |
Why?
|
Appointments and Schedules | 2 | 2014 | 441 | 0.100 |
Why?
|
Bisexuality | 1 | 2014 | 295 | 0.100 |
Why?
|
Aging | 2 | 2022 | 8725 | 0.100 |
Why?
|
Sweet Syndrome | 1 | 2012 | 56 | 0.100 |
Why?
|
Drug Resistance, Multiple, Viral | 1 | 2012 | 52 | 0.100 |
Why?
|
Lymphocyte Activation | 5 | 2012 | 5500 | 0.100 |
Why?
|
Viremia | 5 | 2007 | 727 | 0.100 |
Why?
|
Self Care | 2 | 2014 | 800 | 0.090 |
Why?
|
Genome, Mitochondrial | 1 | 2011 | 68 | 0.090 |
Why?
|
HIV Reverse Transcriptase | 1 | 2012 | 214 | 0.090 |
Why?
|
Amino Acids | 2 | 2015 | 1709 | 0.090 |
Why?
|
Abdominal Wall | 1 | 2012 | 166 | 0.090 |
Why?
|
Lipid Metabolism | 2 | 2017 | 1893 | 0.090 |
Why?
|
Cholesterol, HDL | 1 | 2017 | 1813 | 0.090 |
Why?
|
Seasons | 1 | 2017 | 1522 | 0.090 |
Why?
|
Cardiolipins | 1 | 2010 | 82 | 0.090 |
Why?
|
Colon | 1 | 2018 | 1796 | 0.090 |
Why?
|
Hemorrhagic Fever, Ebola | 1 | 2015 | 424 | 0.090 |
Why?
|
Erythema | 1 | 2011 | 261 | 0.090 |
Why?
|
Cytochrome P-450 CYP3A | 1 | 2010 | 117 | 0.090 |
Why?
|
Genes, MHC Class I | 1 | 2010 | 236 | 0.080 |
Why?
|
Nucleosides | 2 | 2012 | 130 | 0.080 |
Why?
|
HIV Protease Inhibitors | 2 | 2009 | 430 | 0.080 |
Why?
|
Biosensing Techniques | 1 | 2015 | 640 | 0.080 |
Why?
|
Time Factors | 9 | 2016 | 40097 | 0.080 |
Why?
|
Massachusetts | 3 | 2012 | 8882 | 0.080 |
Why?
|
Double-Blind Method | 8 | 2015 | 12417 | 0.080 |
Why?
|
Smoking Cessation | 1 | 2021 | 2084 | 0.080 |
Why?
|
Phosphatidylcholines | 1 | 2010 | 403 | 0.080 |
Why?
|
HIV Seropositivity | 2 | 2012 | 961 | 0.080 |
Why?
|
Epistasis, Genetic | 1 | 2011 | 353 | 0.080 |
Why?
|
Truth Disclosure | 1 | 2012 | 433 | 0.080 |
Why?
|
Post-Exposure Prophylaxis | 1 | 2009 | 113 | 0.080 |
Why?
|
Toll-Like Receptor 7 | 1 | 2009 | 169 | 0.070 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2014 | 4055 | 0.070 |
Why?
|
Cytotoxicity, Immunologic | 2 | 2003 | 1346 | 0.070 |
Why?
|
Cardiomyopathies | 1 | 2020 | 2068 | 0.070 |
Why?
|
Health Behavior | 2 | 2022 | 2649 | 0.070 |
Why?
|
Sexual Partners | 1 | 2012 | 804 | 0.070 |
Why?
|
Receptors, Tumor Necrosis Factor | 1 | 2010 | 588 | 0.070 |
Why?
|
Dementia | 1 | 2022 | 2741 | 0.070 |
Why?
|
Adipose Tissue | 4 | 2020 | 3314 | 0.070 |
Why?
|
Eye Infections, Bacterial | 1 | 2010 | 238 | 0.070 |
Why?
|
Cerebrospinal Fluid | 1 | 2010 | 540 | 0.070 |
Why?
|
Aged | 20 | 2024 | 171163 | 0.070 |
Why?
|
Minority Groups | 1 | 2014 | 1208 | 0.070 |
Why?
|
GB virus C | 1 | 2006 | 9 | 0.070 |
Why?
|
Immunity, Cellular | 2 | 2004 | 1555 | 0.070 |
Why?
|
Infectious Disease Transmission, Patient-to-Professional | 1 | 2009 | 249 | 0.070 |
Why?
|
Crohn Disease | 1 | 2019 | 2281 | 0.070 |
Why?
|
Ambulatory Care Facilities | 1 | 2012 | 937 | 0.070 |
Why?
|
Proteinuria | 1 | 2009 | 606 | 0.070 |
Why?
|
Leukocyte Count | 1 | 2010 | 1605 | 0.070 |
Why?
|
T-Lymphocytes | 3 | 2013 | 10256 | 0.070 |
Why?
|
Sexual Behavior | 2 | 2014 | 2192 | 0.070 |
Why?
|
Dyspnea | 1 | 2014 | 1351 | 0.070 |
Why?
|
Ribavirin | 2 | 2007 | 395 | 0.070 |
Why?
|
Creatinine | 2 | 2009 | 1916 | 0.060 |
Why?
|
Cardiovascular Diseases | 3 | 2022 | 15645 | 0.060 |
Why?
|
Quality of Life | 4 | 2023 | 13463 | 0.060 |
Why?
|
Drug Combinations | 2 | 2014 | 2075 | 0.060 |
Why?
|
Homosexuality, Male | 1 | 2014 | 1342 | 0.060 |
Why?
|
Epitopes, T-Lymphocyte | 4 | 2004 | 825 | 0.060 |
Why?
|
Social Stigma | 1 | 2012 | 787 | 0.060 |
Why?
|
Hepatitis, Viral, Human | 1 | 2006 | 141 | 0.060 |
Why?
|
Virus Integration | 1 | 2008 | 303 | 0.060 |
Why?
|
Drug Monitoring | 1 | 2012 | 960 | 0.060 |
Why?
|
Depression | 4 | 2021 | 8223 | 0.060 |
Why?
|
Malaria | 1 | 2015 | 1246 | 0.060 |
Why?
|
Plasmodium falciparum | 1 | 2015 | 1736 | 0.060 |
Why?
|
Health Literacy | 1 | 2011 | 465 | 0.060 |
Why?
|
Antigen Presentation | 1 | 2010 | 1250 | 0.060 |
Why?
|
Risk Factors | 8 | 2022 | 74850 | 0.060 |
Why?
|
Randomized Controlled Trials as Topic | 6 | 2021 | 10380 | 0.060 |
Why?
|
Relapsing Fever | 1 | 2024 | 26 | 0.060 |
Why?
|
Anxiety | 4 | 2022 | 4669 | 0.060 |
Why?
|
Intra-Abdominal Fat | 1 | 2009 | 624 | 0.060 |
Why?
|
Genome-Wide Association Study | 5 | 2015 | 12803 | 0.060 |
Why?
|
Haplotypes | 4 | 2012 | 2726 | 0.060 |
Why?
|
Medical Records Systems, Computerized | 1 | 2010 | 1195 | 0.050 |
Why?
|
Patient Education as Topic | 2 | 2011 | 2331 | 0.050 |
Why?
|
Cesarean Section | 1 | 2012 | 1418 | 0.050 |
Why?
|
Chronic Disease | 4 | 2011 | 9351 | 0.050 |
Why?
|
Coronary Vessels | 1 | 2015 | 3094 | 0.050 |
Why?
|
Adaptation, Psychological | 1 | 2014 | 2662 | 0.050 |
Why?
|
Young Adult | 9 | 2017 | 59857 | 0.050 |
Why?
|
Polymorphism, Single Nucleotide | 6 | 2015 | 16039 | 0.050 |
Why?
|
Social Support | 3 | 2022 | 2190 | 0.050 |
Why?
|
Brain | 3 | 2021 | 27179 | 0.050 |
Why?
|
Boston | 3 | 2012 | 9334 | 0.050 |
Why?
|
Severity of Illness Index | 1 | 2021 | 15878 | 0.050 |
Why?
|
Digestive System Diseases | 1 | 2024 | 152 | 0.050 |
Why?
|
Receptors, Mineralocorticoid | 1 | 2024 | 167 | 0.050 |
Why?
|
Dendritic Cells | 2 | 2013 | 2745 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 1 | 2012 | 6503 | 0.050 |
Why?
|
Granuloma | 1 | 2024 | 329 | 0.050 |
Why?
|
Cystitis | 1 | 2002 | 96 | 0.050 |
Why?
|
Magnetic Resonance Imaging | 4 | 2024 | 36547 | 0.050 |
Why?
|
Multiple Pulmonary Nodules | 1 | 2024 | 173 | 0.050 |
Why?
|
HLA-DR Antigens | 1 | 2003 | 608 | 0.050 |
Why?
|
Albuminuria | 1 | 2005 | 659 | 0.050 |
Why?
|
BK Virus | 1 | 2002 | 120 | 0.050 |
Why?
|
Gene Products, rev | 1 | 2001 | 29 | 0.050 |
Why?
|
Cholesterol | 1 | 2010 | 2902 | 0.050 |
Why?
|
Virus Replication | 1 | 2009 | 2450 | 0.050 |
Why?
|
DNA, Viral | 1 | 2008 | 2196 | 0.050 |
Why?
|
Gene Products, tat | 1 | 2001 | 111 | 0.040 |
Why?
|
Colonoscopy | 2 | 2019 | 1408 | 0.040 |
Why?
|
Absorptiometry, Photon | 4 | 2008 | 1707 | 0.040 |
Why?
|
Data Collection | 1 | 2010 | 3318 | 0.040 |
Why?
|
Hepatitis C Antigens | 1 | 2000 | 35 | 0.040 |
Why?
|
HLA-A2 Antigen | 1 | 2001 | 207 | 0.040 |
Why?
|
Immunologic Memory | 2 | 2006 | 1374 | 0.040 |
Why?
|
Interleukin-6 | 1 | 2010 | 3225 | 0.040 |
Why?
|
Lung | 2 | 2019 | 10046 | 0.040 |
Why?
|
Inflammation | 2 | 2017 | 10843 | 0.040 |
Why?
|
Self Efficacy | 1 | 2004 | 641 | 0.040 |
Why?
|
Herpesvirus 4, Human | 1 | 2005 | 1077 | 0.040 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2006 | 1362 | 0.040 |
Why?
|
Killer Cells, Natural | 1 | 2009 | 2206 | 0.040 |
Why?
|
Intestine, Large | 1 | 2019 | 69 | 0.040 |
Why?
|
Polymorphism, Genetic | 4 | 2014 | 4249 | 0.040 |
Why?
|
Anti-Bacterial Agents | 2 | 2024 | 7473 | 0.040 |
Why?
|
Longitudinal Studies | 5 | 2007 | 14745 | 0.040 |
Why?
|
Immunization | 1 | 2003 | 1218 | 0.040 |
Why?
|
Sex Characteristics | 1 | 2009 | 2645 | 0.040 |
Why?
|
Decision Making | 1 | 2012 | 3955 | 0.040 |
Why?
|
Sickness Impact Profile | 1 | 2020 | 297 | 0.040 |
Why?
|
Epitopes | 4 | 2010 | 2523 | 0.040 |
Why?
|
Case-Control Studies | 6 | 2017 | 22228 | 0.040 |
Why?
|
Urban Population | 1 | 2007 | 2040 | 0.040 |
Why?
|
Perfusion | 1 | 2023 | 1408 | 0.040 |
Why?
|
Cecum | 1 | 2019 | 231 | 0.040 |
Why?
|
Parasitic Diseases | 1 | 2018 | 76 | 0.040 |
Why?
|
Hydrocarbons, Fluorinated | 1 | 2017 | 40 | 0.040 |
Why?
|
Body Composition | 1 | 2007 | 2441 | 0.040 |
Why?
|
RNA, Messenger | 1 | 2012 | 12768 | 0.040 |
Why?
|
Mutation | 4 | 2012 | 30192 | 0.040 |
Why?
|
Disease Progression | 4 | 2024 | 13614 | 0.040 |
Why?
|
Predictive Value of Tests | 2 | 2021 | 15401 | 0.040 |
Why?
|
Prognosis | 3 | 2021 | 29890 | 0.040 |
Why?
|
Glucose | 1 | 2009 | 4335 | 0.040 |
Why?
|
Protease Inhibitors | 1 | 2001 | 747 | 0.040 |
Why?
|
Acute Disease | 6 | 2006 | 7236 | 0.030 |
Why?
|
Americas | 1 | 2017 | 110 | 0.030 |
Why?
|
Testosterone | 1 | 2007 | 2495 | 0.030 |
Why?
|
Substance-Related Disorders | 1 | 2012 | 4418 | 0.030 |
Why?
|
Bacterial Infections | 1 | 2024 | 1387 | 0.030 |
Why?
|
Family Practice | 1 | 1999 | 508 | 0.030 |
Why?
|
Pilot Projects | 3 | 2022 | 8724 | 0.030 |
Why?
|
Cytarabine | 2 | 1988 | 696 | 0.030 |
Why?
|
United States | 8 | 2022 | 72909 | 0.030 |
Why?
|
Health Personnel | 1 | 2009 | 3385 | 0.030 |
Why?
|
Containment of Biohazards | 1 | 2015 | 39 | 0.030 |
Why?
|
Fibrosis | 1 | 2023 | 2073 | 0.030 |
Why?
|
B-Lymphocytes | 1 | 2009 | 4782 | 0.030 |
Why?
|
Recurrence | 2 | 2024 | 8492 | 0.030 |
Why?
|
Attitude to Health | 1 | 2004 | 2020 | 0.030 |
Why?
|
Gene Expression Regulation | 1 | 2013 | 11895 | 0.030 |
Why?
|
Interferon-gamma | 4 | 2006 | 3158 | 0.030 |
Why?
|
Radiography, Abdominal | 1 | 2018 | 543 | 0.030 |
Why?
|
Liberia | 1 | 2015 | 176 | 0.030 |
Why?
|
Oxidative Stress | 1 | 2006 | 3140 | 0.030 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2024 | 2027 | 0.030 |
Why?
|
Zimbabwe | 1 | 2014 | 135 | 0.030 |
Why?
|
Clinical Trials as Topic | 3 | 2006 | 8037 | 0.030 |
Why?
|
Gene Frequency | 2 | 2012 | 3623 | 0.030 |
Why?
|
Muscle, Skeletal | 1 | 2009 | 4959 | 0.030 |
Why?
|
Bone Marrow | 1 | 2024 | 2916 | 0.030 |
Why?
|
Pharmacogenetics | 2 | 2010 | 682 | 0.030 |
Why?
|
Gelatin | 1 | 2015 | 227 | 0.030 |
Why?
|
Eosinophilia | 1 | 2018 | 553 | 0.030 |
Why?
|
Fear | 1 | 2022 | 1496 | 0.030 |
Why?
|
Multicenter Studies as Topic | 2 | 2014 | 1729 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 3 | 2024 | 20690 | 0.030 |
Why?
|
Natural Language Processing | 1 | 2022 | 1198 | 0.030 |
Why?
|
Recombinant Proteins | 3 | 2009 | 6491 | 0.030 |
Why?
|
Biological Transport | 1 | 2017 | 2081 | 0.030 |
Why?
|
Cells, Cultured | 3 | 2017 | 18962 | 0.030 |
Why?
|
ROC Curve | 1 | 2021 | 3612 | 0.030 |
Why?
|
Molecular Sequence Data | 4 | 2011 | 17596 | 0.030 |
Why?
|
Haiti | 1 | 2014 | 553 | 0.030 |
Why?
|
Outpatients | 1 | 2021 | 1595 | 0.030 |
Why?
|
Radiography, Thoracic | 1 | 2019 | 1319 | 0.030 |
Why?
|
Chiroptera | 1 | 2013 | 62 | 0.030 |
Why?
|
Triglycerides | 1 | 2020 | 2440 | 0.030 |
Why?
|
Liver Cirrhosis | 1 | 2023 | 1961 | 0.020 |
Why?
|
Immunity, Innate | 2 | 2017 | 3078 | 0.020 |
Why?
|
Hepatitis C Antibodies | 2 | 2004 | 151 | 0.020 |
Why?
|
Condoms | 1 | 2014 | 336 | 0.020 |
Why?
|
Adolescent | 9 | 2016 | 88811 | 0.020 |
Why?
|
Bites and Stings | 1 | 2013 | 93 | 0.020 |
Why?
|
Thymidine | 1 | 2012 | 294 | 0.020 |
Why?
|
Electrical Equipment and Supplies | 1 | 2012 | 28 | 0.020 |
Why?
|
Paresthesia | 1 | 2013 | 159 | 0.020 |
Why?
|
Substance Abuse, Intravenous | 1 | 2016 | 527 | 0.020 |
Why?
|
Retrospective Studies | 4 | 2014 | 81537 | 0.020 |
Why?
|
San Francisco | 1 | 2012 | 165 | 0.020 |
Why?
|
Menopause | 1 | 2020 | 1659 | 0.020 |
Why?
|
Peru | 1 | 2014 | 888 | 0.020 |
Why?
|
Cross-Sectional Studies | 4 | 2023 | 26282 | 0.020 |
Why?
|
Botswana | 1 | 2014 | 1057 | 0.020 |
Why?
|
Health Care Surveys | 1 | 1999 | 2426 | 0.020 |
Why?
|
Least-Squares Analysis | 1 | 2012 | 368 | 0.020 |
Why?
|
Blood Glucose | 1 | 2005 | 6422 | 0.020 |
Why?
|
Receptors, Drug | 1 | 2011 | 156 | 0.020 |
Why?
|
Principal Component Analysis | 1 | 2014 | 947 | 0.020 |
Why?
|
History, 21st Century | 1 | 2017 | 1572 | 0.020 |
Why?
|
Brazil | 1 | 2014 | 1248 | 0.020 |
Why?
|
Anticholesteremic Agents | 1 | 2017 | 970 | 0.020 |
Why?
|
HLA-C Antigens | 1 | 2010 | 146 | 0.020 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2020 | 3678 | 0.020 |
Why?
|
Sequence Analysis, DNA | 2 | 2012 | 4780 | 0.020 |
Why?
|
HLA-A Antigens | 1 | 2010 | 223 | 0.020 |
Why?
|
Loneliness | 1 | 2012 | 210 | 0.020 |
Why?
|
Hemorrhage | 1 | 2002 | 3466 | 0.020 |
Why?
|
Phospholipases A | 1 | 1990 | 204 | 0.020 |
Why?
|
Potassium Channels, Inwardly Rectifying | 1 | 2011 | 144 | 0.020 |
Why?
|
Models, Psychological | 1 | 2014 | 823 | 0.020 |
Why?
|
Shock | 1 | 2012 | 316 | 0.020 |
Why?
|
HIV Long-Term Survivors | 1 | 2010 | 140 | 0.020 |
Why?
|
Postoperative Complications | 1 | 2012 | 15802 | 0.020 |
Why?
|
Oligopeptides | 2 | 2009 | 1193 | 0.020 |
Why?
|
Reproducibility of Results | 2 | 2022 | 20133 | 0.020 |
Why?
|
HIV Antigens | 1 | 2010 | 328 | 0.020 |
Why?
|
Research Personnel | 1 | 2014 | 589 | 0.020 |
Why?
|
Kinetics | 2 | 2008 | 6273 | 0.020 |
Why?
|
Uganda | 1 | 2014 | 1353 | 0.020 |
Why?
|
Blood-Borne Pathogens | 1 | 2009 | 51 | 0.020 |
Why?
|
Quality-Adjusted Life Years | 1 | 2016 | 1740 | 0.020 |
Why?
|
Prospective Studies | 5 | 2021 | 54807 | 0.020 |
Why?
|
Membrane Proteins | 1 | 2006 | 7847 | 0.020 |
Why?
|
Needlestick Injuries | 1 | 2009 | 71 | 0.020 |
Why?
|
Life Style | 1 | 2021 | 3928 | 0.020 |
Why?
|
South Africa | 1 | 2014 | 1868 | 0.020 |
Why?
|
Pulmonary Emphysema | 1 | 2014 | 683 | 0.020 |
Why?
|
Models, Theoretical | 1 | 2021 | 3560 | 0.020 |
Why?
|
Risk-Taking | 1 | 2014 | 1021 | 0.020 |
Why?
|
Counseling | 1 | 2016 | 1551 | 0.020 |
Why?
|
Liver Neoplasms | 1 | 2024 | 4349 | 0.020 |
Why?
|
Mental Health | 1 | 2022 | 3272 | 0.020 |
Why?
|
Drosophila Proteins | 1 | 2017 | 1704 | 0.020 |
Why?
|
Necrosis | 1 | 2012 | 1611 | 0.020 |
Why?
|
Fatal Outcome | 1 | 2013 | 1835 | 0.020 |
Why?
|
Critical Illness | 1 | 2021 | 2749 | 0.020 |
Why?
|
Sulfonamides | 1 | 2017 | 1979 | 0.020 |
Why?
|
Prevalence | 2 | 2020 | 15828 | 0.020 |
Why?
|
Nurse-Patient Relations | 1 | 2008 | 101 | 0.020 |
Why?
|
ATP-Binding Cassette Transporters | 1 | 2011 | 566 | 0.020 |
Why?
|
Algorithms | 2 | 2022 | 14064 | 0.020 |
Why?
|
Ritonavir | 1 | 2009 | 331 | 0.020 |
Why?
|
Headache | 1 | 2015 | 1261 | 0.020 |
Why?
|
Intensive Care Units | 1 | 2021 | 3799 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2013 | 3430 | 0.020 |
Why?
|
Malaria, Falciparum | 1 | 2015 | 1073 | 0.020 |
Why?
|
Amino Acid Sequence | 3 | 2004 | 13398 | 0.020 |
Why?
|
Clinical Protocols | 1 | 2012 | 1435 | 0.020 |
Why?
|
Deglutition Disorders | 1 | 2013 | 640 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2012 | 2844 | 0.020 |
Why?
|
Microbial Sensitivity Tests | 1 | 2013 | 1970 | 0.020 |
Why?
|
Pyrimidinones | 1 | 2009 | 384 | 0.020 |
Why?
|
HIV Core Protein p24 | 1 | 2006 | 245 | 0.020 |
Why?
|
Colonic Neoplasms | 1 | 2018 | 2530 | 0.020 |
Why?
|
Base Sequence | 2 | 2011 | 12405 | 0.020 |
Why?
|
Adenine | 1 | 2012 | 994 | 0.020 |
Why?
|
Bayes Theorem | 1 | 2014 | 2353 | 0.020 |
Why?
|
Animals | 4 | 2017 | 168735 | 0.020 |
Why?
|
Electroencephalography | 1 | 2021 | 6274 | 0.020 |
Why?
|
Tuberculosis | 1 | 2018 | 2009 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2021 | 14643 | 0.020 |
Why?
|
Sleep | 1 | 2021 | 4818 | 0.020 |
Why?
|
Lung Diseases, Interstitial | 1 | 2014 | 940 | 0.020 |
Why?
|
Comorbidity | 2 | 2012 | 10575 | 0.020 |
Why?
|
Cholesterol, LDL | 1 | 2015 | 2395 | 0.020 |
Why?
|
Interpersonal Relations | 1 | 2012 | 1432 | 0.020 |
Why?
|
Electronic Health Records | 1 | 2022 | 4863 | 0.010 |
Why?
|
Progesterone | 1 | 2009 | 751 | 0.010 |
Why?
|
Cognition | 1 | 2022 | 7043 | 0.010 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2017 | 2184 | 0.010 |
Why?
|
Lymphocyte Count | 1 | 2006 | 791 | 0.010 |
Why?
|
Maximum Tolerated Dose | 1 | 2007 | 895 | 0.010 |
Why?
|
Medicare | 1 | 2022 | 6815 | 0.010 |
Why?
|
Exercise | 1 | 2021 | 5936 | 0.010 |
Why?
|
Remission, Spontaneous | 1 | 2004 | 384 | 0.010 |
Why?
|
California | 1 | 2008 | 1435 | 0.010 |
Why?
|
Cost-Benefit Analysis | 1 | 2016 | 5531 | 0.010 |
Why?
|
Plaque, Atherosclerotic | 1 | 2015 | 1529 | 0.010 |
Why?
|
Genetic Association Studies | 1 | 2012 | 2744 | 0.010 |
Why?
|
Radiography | 1 | 2014 | 6941 | 0.010 |
Why?
|
Body Size | 1 | 2006 | 460 | 0.010 |
Why?
|
Placenta | 1 | 2012 | 1726 | 0.010 |
Why?
|
Immunoassay | 1 | 2006 | 742 | 0.010 |
Why?
|
Cytochrome P-450 Enzyme System | 1 | 2005 | 423 | 0.010 |
Why?
|
Hematologic Diseases | 1 | 2007 | 500 | 0.010 |
Why?
|
Pregnancy | 2 | 2017 | 30230 | 0.010 |
Why?
|
Protein Conformation | 1 | 2010 | 3945 | 0.010 |
Why?
|
Pandemics | 1 | 2022 | 8721 | 0.010 |
Why?
|
Genes, MHC Class II | 1 | 2003 | 433 | 0.010 |
Why?
|
Interferons | 1 | 2006 | 714 | 0.010 |
Why?
|
Body Mass Index | 1 | 2020 | 13042 | 0.010 |
Why?
|
Linear Models | 1 | 2012 | 5873 | 0.010 |
Why?
|
Age Factors | 2 | 2012 | 18382 | 0.010 |
Why?
|
Leukemia, Myeloid, Acute | 2 | 1988 | 3637 | 0.010 |
Why?
|
Demography | 1 | 2006 | 1640 | 0.010 |
Why?
|
rev Gene Products, Human Immunodeficiency Virus | 1 | 2001 | 26 | 0.010 |
Why?
|
Qualitative Research | 1 | 2012 | 3136 | 0.010 |
Why?
|
Gene Products, vpr | 1 | 2001 | 33 | 0.010 |
Why?
|
vpr Gene Products, Human Immunodeficiency Virus | 1 | 2001 | 36 | 0.010 |
Why?
|
Cohort Studies | 3 | 2010 | 41680 | 0.010 |
Why?
|
tat Gene Products, Human Immunodeficiency Virus | 1 | 2001 | 119 | 0.010 |
Why?
|
Hospitalization | 1 | 2021 | 10810 | 0.010 |
Why?
|
Feasibility Studies | 1 | 2012 | 5300 | 0.010 |
Why?
|
Models, Molecular | 1 | 2010 | 5377 | 0.010 |
Why?
|
Peptides | 2 | 2003 | 4331 | 0.010 |
Why?
|
Polyomavirus Infections | 1 | 2002 | 193 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 3 | 2006 | 18074 | 0.010 |
Why?
|
Gene Products, gag | 1 | 2000 | 317 | 0.010 |
Why?
|
Genome, Human | 1 | 2012 | 4443 | 0.010 |
Why?
|
Tumor Virus Infections | 1 | 2002 | 438 | 0.010 |
Why?
|
Alleles | 1 | 2010 | 6891 | 0.010 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 1990 | 4342 | 0.010 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 4563 | 0.010 |
Why?
|
Occupational Exposure | 1 | 2009 | 1806 | 0.010 |
Why?
|
HLA Antigens | 1 | 2004 | 1338 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2012 | 12059 | 0.010 |
Why?
|
Italy | 1 | 2001 | 851 | 0.010 |
Why?
|
Computational Biology | 1 | 2011 | 3562 | 0.010 |
Why?
|
Dyslipidemias | 1 | 2005 | 871 | 0.010 |
Why?
|
Transcription Factors | 1 | 2017 | 12129 | 0.010 |
Why?
|
Interleukin-2 | 1 | 2004 | 1894 | 0.010 |
Why?
|
Pyridines | 1 | 2009 | 2885 | 0.010 |
Why?
|
Viral Vaccines | 1 | 2002 | 596 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2013 | 9525 | 0.010 |
Why?
|
Software | 1 | 2011 | 4462 | 0.010 |
Why?
|
Models, Genetic | 1 | 2006 | 3447 | 0.010 |
Why?
|
Regression Analysis | 1 | 2006 | 6321 | 0.010 |
Why?
|
DNA Primers | 1 | 2001 | 2824 | 0.010 |
Why?
|
Viral Proteins | 1 | 2003 | 1798 | 0.010 |
Why?
|
Logistic Models | 1 | 2010 | 13273 | 0.010 |
Why?
|
Genomics | 1 | 2012 | 5925 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2004 | 6202 | 0.010 |
Why?
|
Flow Cytometry | 1 | 2006 | 5880 | 0.010 |
Why?
|
Body Weight | 1 | 2006 | 4627 | 0.010 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2002 | 1374 | 0.010 |
Why?
|
Lipids | 1 | 2005 | 3317 | 0.010 |
Why?
|
Salvage Therapy | 1 | 2001 | 1272 | 0.010 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2003 | 2570 | 0.010 |
Why?
|
DNA | 1 | 1987 | 7193 | 0.010 |
Why?
|
Phenotype | 1 | 2012 | 16714 | 0.010 |
Why?
|
Delivery of Health Care | 1 | 2011 | 5364 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2010 | 7423 | 0.010 |
Why?
|
Drug Administration Schedule | 1 | 2000 | 4851 | 0.010 |
Why?
|
Binding Sites | 1 | 2001 | 5999 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2013 | 39228 | 0.010 |
Why?
|
Cell Line | 2 | 2001 | 15540 | 0.010 |
Why?
|
Insulin Resistance | 1 | 2005 | 3988 | 0.010 |
Why?
|
Tumor Cells, Cultured | 2 | 1990 | 6101 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2006 | 12529 | 0.010 |
Why?
|
Quinacrine | 1 | 1990 | 24 | 0.010 |
Why?
|
Health Status | 1 | 2004 | 4085 | 0.010 |
Why?
|
Acetophenones | 1 | 1990 | 51 | 0.010 |
Why?
|
Lysophosphatidylcholines | 1 | 1990 | 77 | 0.010 |
Why?
|
Lipoxygenase Inhibitors | 1 | 1990 | 93 | 0.010 |
Why?
|
Inositol Phosphates | 1 | 1990 | 174 | 0.010 |
Why?
|
Phospholipases A2 | 1 | 1990 | 197 | 0.010 |
Why?
|
Mice | 1 | 2017 | 81782 | 0.010 |
Why?
|
Arachidonic Acids | 1 | 1990 | 293 | 0.010 |
Why?
|
Type C Phospholipases | 1 | 1990 | 284 | 0.010 |
Why?
|
Precipitin Tests | 1 | 1990 | 812 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2007 | 11639 | 0.010 |
Why?
|
Arachidonic Acid | 1 | 1990 | 429 | 0.000 |
Why?
|
Blotting, Northern | 1 | 1990 | 1546 | 0.000 |
Why?
|
Choline | 1 | 1990 | 511 | 0.000 |
Why?
|
Stress, Psychological | 1 | 2004 | 4527 | 0.000 |
Why?
|
Leukemia, Myeloid | 1 | 1990 | 695 | 0.000 |
Why?
|
Radioimmunoassay | 1 | 1987 | 860 | 0.000 |
Why?
|
Aged, 80 and over | 1 | 2010 | 59496 | 0.000 |
Why?
|
Enzyme Activation | 1 | 1990 | 3583 | 0.000 |
Why?
|
Child, Preschool | 1 | 2007 | 42510 | 0.000 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 1987 | 1527 | 0.000 |
Why?
|
Hydrogen-Ion Concentration | 1 | 1987 | 2476 | 0.000 |
Why?
|
Child | 1 | 2007 | 80568 | 0.000 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 1990 | 8603 | 0.000 |
Why?
|